These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38317053)

  • 21. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H; Yu DA; Kwon O
    J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
    Kim H; Dill S; O'Brien M; Vian L; Li X; Manukyan M; Jain M; Adeojo LW; George J; Perez M; Grom AA; Sutter M; Feldman BM; Yao L; Millwood M; Brundidge A; Pichard DC; Cowen EW; Shi Y; Lu S; Tsai WL; Gadina M; Rider LG; Colbert RA
    Ann Rheum Dis; 2021 Mar; 80(3):406-408. PubMed ID: 32843325
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA.
    Amrhein J; Drynda S; Schlatt L; Karst U; Lohmann CH; Ciarimboli G; Bertrand J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
    Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
    Chen M; Dai SM
    Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
    Dhir B; Meena SK; Sardana K; Sharath S
    Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
    Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R
    Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSs.
    Bonelli M; Dalwigk K; Platzer A; Olmos Calvo I; Hayer S; Niederreiter B; Holinka J; Sevelda F; Pap T; Steiner G; Superti-Furga G; Smolen JS; Kiener HP; Karonitsch T
    Exp Mol Med; 2019 Jul; 51(7):1-11. PubMed ID: 31285419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
    Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
    Taylor PC
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta-Analysis.
    Giménez Poderós T; Gallardo Borge S; Vazquez-Ferreiro P
    Pharmacotherapy; 2020 Dec; 40(12):1248-1264. PubMed ID: 33064892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
    Collotta D; Hull W; Mastrocola R; Chiazza F; Cento AS; Murphy C; Verta R; Alves GF; Gaudioso G; Fava F; Yaqoob M; Aragno M; Tuohy K; Thiemermann C; Collino M
    Mol Metab; 2020 Sep; 39():101009. PubMed ID: 32413585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's disease.
    Gupta S; Yamada E; Nakamura H; Perez P; Pranzatelli TJ; Dominick K; Jang SI; Abed M; Martin D; Burbelo P; Zheng C; French B; Alevizos I; Khavandgar Z; Beach M; Pelayo E; Walitt B; Hasni S; Kaplan MJ; Tandon M; Magone MT; Kleiner DE; Chiorini JA; Baer A; Warner BM
    Ann Rheum Dis; 2024 Jul; 83(8):1034-1047. PubMed ID: 38527764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. National and interprovincial prescribing patterns of JAK-inhibitors in Canada: a repeated cross-sectional analysis.
    Saunders KC; Shakeri A; Chu C; Drucker AM; Tadrous M
    Clin Rheumatol; 2024 Oct; 43(10):3083-3088. PubMed ID: 39198358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.
    Ladislau L; Suárez-Calvet X; Toquet S; Landon-Cardinal O; Amelin D; Depp M; Rodero MP; Hathazi D; Duffy D; Bondet V; Preusse C; Bienvenu B; Rozenberg F; Roos A; Benjamim CF; Gallardo E; Illa I; Mouly V; Stenzel W; Butler-Browne G; Benveniste O; Allenbach Y
    Brain; 2018 Jun; 141(6):1609-1621. PubMed ID: 29741608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [JAK Inhibitors in Rheumatology].
    Witte T
    Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
    Mitchell TS; Moots RJ; Wright HL
    Clin Exp Immunol; 2017 Aug; 189(2):250-258. PubMed ID: 28369741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.